Program See Boxed Warning News Today

UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology Annual Meeting Diverse and...

Study presents new persistence analysis of FINTEPLA, evaluating the efficacy and tolerability of FINTEPLA over a span of 12 months1 Real-world data looks into the need for resources to support caregivers – both parents and siblings – of people living with developmental and epileptic encephalopathies such as Dravet and Lennox-Gastaut syndromes in the transition from […]

UCB will present 29 abstracts, including 4 late breakers, at American Epilepsy Society Annual Meeting 2023 highlighting clinical, health economic and...

21 scientific presentations, including 7 late breakers, showcase the breadth of UCBs portfolio, reinforcing commitment to improving the lives of people living...

Peer-reviewed results from the Phase 3 open-label extension study of FINTEPLA® in LGS provide significant reduction in the frequency of multiple seizure types...

Primary endpoint was met demonstrating that FINTEPLA, as adjunctive treatment, is effective in significantly reducing the frequency of drop seizures in LGS...

Primary endpoint was met demonstrating that FINTEPLA, as adjunctive treatment, is effective in significantly reducing the frequency of drop seizur...

FINTEPLA® has demonstrated efficacy in the most difficult-to-treat seizure types,1,2 including drop seizures, which cause a person to suddenly lose muscle...

UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ: ZGNX) for US$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share. The total transaction is valued at up to approximately US ...

/PRNewswire/ -- UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ: ZGNX) for US$...